These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24632934)

  • 1. New drugs: simeprevir, sofosbuvir, and dolutegravir sodium.
    Hussar DA; Jin ZJ
    J Am Pharm Assoc (2003); 2014; 54(2):202-7. PubMed ID: 24632934
    [No Abstract]   [Full Text] [Related]  

  • 2. WHO issues guidelines on HCV amid drug cost controversy.
    Slomski A
    JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
    [No Abstract]   [Full Text] [Related]  

  • 3. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
    Ollendorf DA; Tice JA; Pearson SD
    JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321
    [No Abstract]   [Full Text] [Related]  

  • 4. The high price of the new hepatitis C virus drugs.
    Steinbrook R; Redberg RF
    JAMA Intern Med; 2014 Jul; 174(7):1172. PubMed ID: 24798183
    [No Abstract]   [Full Text] [Related]  

  • 5. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
    Campos-Varela I; Straley S; Agudelo EZ; Carlson L; Terrault NA
    Liver Transpl; 2015 Feb; 21(2):272-4. PubMed ID: 25332190
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA approvals usher in the post-interferon era in HCV.
    Sheridan C
    Nat Biotechnol; 2014 Jan; 32(1):3-5. PubMed ID: 24406908
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicine. Hepatitis C can be cured globally, but at what cost?
    Hill A; Cooke G
    Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
    [No Abstract]   [Full Text] [Related]  

  • 8. New drugs 2014, part 2.
    Hussar DA
    Nursing; 2014 Jul; 44(7):26-33; quiz 33-4. PubMed ID: 24905857
    [No Abstract]   [Full Text] [Related]  

  • 9. The rapid evolution of treatment strategies for hepatitis C.
    Muir AJ
    Am J Gastroenterol; 2014 May; 109(5):628-35; quiz 636. PubMed ID: 24732866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The price of good health.
    Nat Med; 2014 Apr; 20(4):319. PubMed ID: 24710362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new era in therapy of chronic hepatitis C].
    Füessl HS
    MMW Fortschr Med; 2015 Feb; 157(2):38. PubMed ID: 25743515
    [No Abstract]   [Full Text] [Related]  

  • 12. Simeprevir for hepatitis C virus.
    Hutcheson S; Klibanov OM
    Nurse Pract; 2014 Sep; 39(9):10-2. PubMed ID: 25140845
    [No Abstract]   [Full Text] [Related]  

  • 13. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of chronic hepatitis C virus infection in the near future.
    Cheinquer H
    Ann Hepatol; 2013; 12(6):854-9. PubMed ID: 24114813
    [No Abstract]   [Full Text] [Related]  

  • 15. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
    Pungpapong S; Aqel B; Leise M; Werner KT; Murphy JL; Henry TM; Ryland K; Chervenak AE; Watt KD; Vargas HE; Keaveny AP
    Hepatology; 2015 Jun; 61(6):1880-6. PubMed ID: 25722203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New combination therapy increases chances of recovery].
    Jäger-Becker D
    MMW Fortschr Med; 2015 Feb; 157(3):70. PubMed ID: 25743682
    [No Abstract]   [Full Text] [Related]  

  • 17. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
    Hill A; Khoo S; Fortunak J; Simmons B; Ford N
    Clin Infect Dis; 2014 Apr; 58(7):928-36. PubMed ID: 24399087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.
    Berden FA; Kievit W; Baak LC; Bakker CM; Beuers U; Boucher CA; Brouwer JT; Burger DM; van Erpecum KJ; van Hoek B; Hoepelman AI; Honkoop P; Kerbert-Dreteler MJ; de Knegt RJ; Koek GH; van Nieuwkerk CM; van Soest H; Tan AC; Vrolijk JM; Drenth JP
    Neth J Med; 2014 Oct; 72(8):388-400. PubMed ID: 25387551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What are the management issues for hepatitis C in dialysis patients?: natural history of hepatitis C in dialysis populations.
    Carrion AF; Martin P
    Semin Dial; 2014; 27(5):446-8. PubMed ID: 25204876
    [No Abstract]   [Full Text] [Related]  

  • 20. [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
    Chtioui H; Buclin T; Moradpour D
    Rev Med Suisse; 2014 Sep; 10(440):1600-4, 1606. PubMed ID: 25276998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.